These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18246859)

  • 1. Agomelatine: a novel atypical antidepressant.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2007 Dec; 45(12):13-7. PubMed ID: 18246859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focus on agomelatine.
    Green B
    Curr Med Res Opin; 2011 Apr; 27(4):745-9. PubMed ID: 21271795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A benefit-risk assessment of agomelatine in the treatment of major depression.
    Howland RH
    Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].
    Lôo H; Daléry J; Macher JP; Payen A
    Encephale; 2003; 29(2):165-71. PubMed ID: 14567168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study of the efficacy and safety of valdoxan in the treatment of a depressive episode].
    Soldatkin VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(9):36-42. PubMed ID: 24107878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Could agomelatine be the ideal antidepressant?
    Pandi-Perumal SR; Srinivasan V; Cardinali DP; Monti MJ
    Expert Rev Neurother; 2006 Nov; 6(11):1595-608. PubMed ID: 17144776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
    Gupta K; Gupta R; Bhatia MS; Tripathi AK; Gupta LK
    J Clin Pharmacol; 2017 Dec; 57(12):1519-1526. PubMed ID: 28833192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of a new antidepressant : agomelatine].
    Mocaër E; Delalleau B; Boyer PA; de Bodinat C
    Med Sci (Paris); 2005 Oct; 21(10):888-93. PubMed ID: 16197911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of antidepressants in clinical practice: focus on agomelatine.
    McAllister-Williams RH; Baldwin DS; Haddad PM; Bazire S
    Hum Psychopharmacol; 2010 Mar; 25(2):95-102. PubMed ID: 20196187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agomelatine for major depressive episodes.
    Drug Ther Bull; 2010 Aug; 48(8):93-6. PubMed ID: 20685900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine in depression.
    Smeraldi E; Delmonte D
    Expert Opin Drug Saf; 2013 Nov; 12(6):873-80. PubMed ID: 24033095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
    Rouillon F
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.